FDA Approves Monthly Dosing for Leqembi
Source: Reuters, January 26, 2025 In a groundbreaking development for Alzheimer’s patients and their caregivers, the U.S. Food and Drug Administration (FDA) recently approved a monthly
Bipartisan Legislation Strengthens Alzheimer’s Public Health Infrastructure
In a significant victory for Alzheimer’s advocacy, the U.S. House of Representatives has approved bipartisan legislation to strengthen the country’s public health response to Alzheimer’s and
New Cellular Mechanism Discovery Offers Hope for Alzheimer’s Treatment
Researchers have identified a novel cellular mechanism that could play a pivotal role in maintaining brain energy levels and combating neurodegenerative diseases such as Alzheimer’s. This
Groundbreaking Test Predicts Dementia Nine Years Before Diagnosis
In a significant breakthrough in the field of neurodegenerative diseases, researchers at Queen Mary University of London have developed a pioneering test capable of predicting dementia
Predictive Models for Cognitive Decline: A New Frontier in Alzheimer’s Research
Recent advancements in Alzheimer’s research have introduced predictive models that offer new insights into the progression of cognitive decline in patients with early Alzheimer’s disease. These
FDA Approval of Donanemab (Kisunla™): A Breakthrough in Alzheimer’s Treatment
In a significant milestone for Alzheimer’s disease treatment, the U.S. Food and Drug Administration (FDA) recently approved a new drug, Kisunla™ (donanemab-azbt). This approval marks a
Remembering Bud Harrelson, A Champion for Alzheimer’s Awareness
New York Mets legend Bud Harrelson, who bravely shared his Alzheimer’s diagnosis in 2018, passed away earlier this year. Harrelson, renowned for his career as a
Breakthrough in Stress Response Research Offers New Hope for Alzheimer’s Treatment
UC Berkeley scientists have made a significant breakthrough in understanding how stress responses in brain cells can be turned off, a discovery that could pave the
2024 Alzheimer’s Drug Development Pipeline: Hope on the Horizon
The Alzheimer’s drug development pipeline for 2024 is bustling with activity, featuring 171 ongoing studies and 134 drugs in clinical trials. Notable treatments in the pipeline
Innovative Group Training Tool for Dementia Prevention Unveiled
Researchers at Ruhr-University Bochum have developed a groundbreaking group training tool aimed at preventing dementia. This innovative tool focuses on cognitive training and lifestyle changes to